Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotech gets EU panel nod for breast cancer drug, Health News, ET HealthWorld
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib | Seeking Alpha
Puma Biotechnology
Puma Biotechnology
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Puma Biotechnology Surging
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
PumaBiotech (@pumabiotech) / Twitter
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Puma Biotechnology, Inc.
Puma Biotechnology falls more than 20%
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
